[Potential antiviral therapeutics for 2019 Novel Coronavirus].
Identifieur interne : 000019 ( PubMed/Checkpoint ); précédent : 000018; suivant : 000020[Potential antiviral therapeutics for 2019 Novel Coronavirus].
Auteurs : H. Li [République populaire de Chine] ; Y M Wang [République populaire de Chine] ; J Y Xu [République populaire de Chine] ; B. Cao [République populaire de Chine]Source :
- Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases [ 1001-0939 ] ; 2020.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux (usage thérapeutique), Antiviraux (usage thérapeutique), Chine, Coronavirus du syndrome respiratoire du Moyen-Orient, Humains, Infections à coronavirus (traitement médicamenteux), Inhibiteurs du cytochrome P-450 CYP3A (usage thérapeutique), Interféron bêta, Lopinavir (usage thérapeutique), Pneumopathie virale (traitement médicamenteux), Ritonavir (usage thérapeutique), Syndrome respiratoire aigu sévère (traitement médicamenteux).
- MESH :
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale, Syndrome respiratoire aigu sévère.
- usage thérapeutique : Anticorps monoclonaux, Antiviraux, Inhibiteurs du cytochrome P-450 CYP3A, Lopinavir, Ritonavir.
- Chine, Coronavirus du syndrome respiratoire du Moyen-Orient, Humains, Interféron bêta.
- Wicri :
- geographic : République populaire de Chine.
English descriptors
- KwdEn :
- Antibodies, Monoclonal (therapeutic use), Antiviral Agents (therapeutic use), Betacoronavirus (drug effects), China, Coronavirus Infections (drug therapy), Cytochrome P-450 CYP3A Inhibitors (therapeutic use), Humans, Interferon-beta, Lopinavir (therapeutic use), Middle East Respiratory Syndrome Coronavirus, Pneumonia, Viral (drug therapy), Ritonavir (therapeutic use), Severe Acute Respiratory Syndrome (drug therapy).
- MESH :
- chemical , therapeutic use : Antibodies, Monoclonal, Antiviral Agents, Cytochrome P-450 CYP3A Inhibitors, Lopinavir, Ritonavir.
- geographic : China, Interferon-beta.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral, Severe Acute Respiratory Syndrome.
- Humans, Middle East Respiratory Syndrome Coronavirus.
Abstract
The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains-severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir/ritonavir, lopinavir/ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.
DOI: 10.3760/cma.j.issn.1001-0939.2020.03.004
PubMed: 32164080
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32164080Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Potential antiviral therapeutics for 2019 Novel Coronavirus].</title>
<author><name sortKey="Li, H" sort="Li, H" uniqKey="Li H" first="H" last="Li">H. Li</name>
<affiliation wicri:level="1"><nlm:affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Y M" sort="Wang, Y M" uniqKey="Wang Y" first="Y M" last="Wang">Y M Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Xu, J Y" sort="Xu, J Y" uniqKey="Xu J" first="J Y" last="Xu">J Y Xu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing 100084, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing 100084</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cao, B" sort="Cao, B" uniqKey="Cao B" first="B" last="Cao">B. Cao</name>
<affiliation wicri:level="1"><nlm:affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32164080</idno>
<idno type="pmid">32164080</idno>
<idno type="doi">10.3760/cma.j.issn.1001-0939.2020.03.004</idno>
<idno type="wicri:Area/PubMed/Corpus">000642</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000642</idno>
<idno type="wicri:Area/PubMed/Curation">000642</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000642</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000019</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000019</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Potential antiviral therapeutics for 2019 Novel Coronavirus].</title>
<author><name sortKey="Li, H" sort="Li, H" uniqKey="Li H" first="H" last="Li">H. Li</name>
<affiliation wicri:level="1"><nlm:affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Y M" sort="Wang, Y M" uniqKey="Wang Y" first="Y M" last="Wang">Y M Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Xu, J Y" sort="Xu, J Y" uniqKey="Xu J" first="J Y" last="Xu">J Y Xu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing 100084, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing 100084</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cao, B" sort="Cao, B" uniqKey="Cao B" first="B" last="Cao">B. Cao</name>
<affiliation wicri:level="1"><nlm:affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</title>
<idno type="ISSN">1001-0939</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (drug effects)</term>
<term>China</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Cytochrome P-450 CYP3A Inhibitors (therapeutic use)</term>
<term>Humans</term>
<term>Interferon-beta</term>
<term>Lopinavir (therapeutic use)</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Ritonavir (therapeutic use)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Chine</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Humains</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Inhibiteurs du cytochrome P-450 CYP3A (usage thérapeutique)</term>
<term>Interféron bêta</term>
<term>Lopinavir (usage thérapeutique)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Ritonavir (usage thérapeutique)</term>
<term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antiviral Agents</term>
<term>Cytochrome P-450 CYP3A Inhibitors</term>
<term>Lopinavir</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>China</term>
<term>Interferon-beta</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term>
<term>Antiviraux</term>
<term>Inhibiteurs du cytochrome P-450 CYP3A</term>
<term>Lopinavir</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Chine</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Humains</term>
<term>Interféron bêta</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>République populaire de Chine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains-severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir/ritonavir, lopinavir/ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32164080</PMID>
<DateCompleted><Year>2020</Year>
<Month>03</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1001-0939</ISSN>
<JournalIssue CitedMedium="Print"><Volume>43</Volume>
<Issue>3</Issue>
<PubDate><Year>2020</Year>
<Month>Mar</Month>
<Day>12</Day>
</PubDate>
</JournalIssue>
<Title>Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</Title>
<ISOAbbreviation>Zhonghua Jie He He Hu Xi Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Potential antiviral therapeutics for 2019 Novel Coronavirus].</ArticleTitle>
<Pagination><MedlinePgn>170-172</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.issn.1001-0939.2020.03.004</ELocationID>
<Abstract><AbstractText>The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains-severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir/ritonavir, lopinavir/ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Y M</ForeName>
<Initials>YM</Initials>
<AffiliationInfo><Affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Xu</LastName>
<ForeName>J Y</ForeName>
<Initials>JY</Initials>
<AffiliationInfo><Affiliation>Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing 100084, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cao</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Center of Respiratory Medicine, China-Japan Friendship Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; National Clinical Research Center for Respiratory Diseases, Beijing 100020, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Zhonghua Jie He He Hu Xi Za Zhi</MedlineTA>
<NlmUniqueID>8712226</NlmUniqueID>
<ISSNLinking>1001-0939</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D065692">Cytochrome P-450 CYP3A Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2494G1JF75</RegistryNumber>
<NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>77238-31-4</RegistryNumber>
<NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>O3J8G9O825</RegistryNumber>
<NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065692" MajorTopicYN="N">Cytochrome P-450 CYP3A Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherAbstract Type="Publisher" Language="chi"><AbstractText>2019新型冠状病毒(2019-nCoV)是武汉不明原因肺炎的致病原。2019-nCoV在遗传学上与一种蝙蝠来源的新型冠状病毒比较接近,与SARS-CoⅤ、MERS-CoV同为β属冠状病毒。目前临床上常用的抗病毒药物,包括神经氨酸酶抑制剂(奥司他韦、帕拉米韦、扎那米韦等)、更昔洛韦、阿昔洛韦、利巴韦林等药物对2019-nCoV均无效,不建议临床应用。目前研究证实可能有效的药物包括:瑞德西韦、洛匹那韦/利托那韦、洛匹那韦/利托那韦联合干扰素-β、恢复期血浆、单克隆抗体。但这些药物在2019-nCoV肺炎患者中的疗效和安全性有待进一步临床实验证实。.</AbstractText>
</OtherAbstract>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2019 novel coronavirus</Keyword>
<Keyword MajorTopicYN="N">Antiviral therapy</Keyword>
<Keyword MajorTopicYN="N">Infection</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>3</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>3</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>3</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32164080</ArticleId>
<ArticleId IdType="doi">10.3760/cma.j.issn.1001-0939.2020.03.004</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
<settlement><li>Pékin</li>
</settlement>
</list>
<tree><country name="République populaire de Chine"><noRegion><name sortKey="Li, H" sort="Li, H" uniqKey="Li H" first="H" last="Li">H. Li</name>
</noRegion>
<name sortKey="Cao, B" sort="Cao, B" uniqKey="Cao B" first="B" last="Cao">B. Cao</name>
<name sortKey="Wang, Y M" sort="Wang, Y M" uniqKey="Wang Y" first="Y M" last="Wang">Y M Wang</name>
<name sortKey="Xu, J Y" sort="Xu, J Y" uniqKey="Xu J" first="J Y" last="Xu">J Y Xu</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000019 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000019 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:32164080 |texte= [Potential antiviral therapeutics for 2019 Novel Coronavirus]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32164080" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |